Literature DB >> 21146890

HIV infection increases HCV-induced hepatocyte apoptosis.

Jae Young Jang1, Run-Xuan Shao, Wenyu Lin, Ethan Weinberg, Woo Jin Chung, Wei Lun Tsai, Hong Zhao, Kaku Goto, Leiliang Zhang, Jorge Mendez-Navarro, Nikolaus Jilg, Lee F Peng, Mark A Brockman, Raymond T Chung.   

Abstract

BACKGROUND & AIMS: HCV related liver disease is one of the most important complications in persons with HIV, with accelerated fibrosis progression in coinfected persons compared to those with HCV alone. We hypothesized that HCV-HIV coinfection increases HCV related hepatocyte apoptosis and that HCV and HIV influence TRAIL signaling in hepatocytes.
METHODS: We analyzed the effect of HIV in JFH1-infected Huh7.5.1 cells. Apoptosis was measured by Caspase-Glo 3/7 assay and Western blotting for cleaved PARP. TRAIL, TRAIL receptor 1 (DR4), and 2 (DR5) mRNA and protein levels were assessed by real-time PCR and Western blot, respectively. We also investigated activation of caspase pathways using caspase inhibitors and assessed expression of Bid and cytochrome C.
RESULTS: We found increased caspase 3/7 activity and cleaved PARP in JFH1 HCV-infected Huh7.5.1 cells in the presence of heat-inactivated HIV, compared to Huh7.5.1 cells infected with JFH1 or exposed to heat-inactivated HIV alone. Both DR4 and DR5 mRNA and protein expression were increased in JFH1-infected cells in the presence of inactivated HIV compared to Huh7.5.1 cells infected with JFH1 or exposed to heat-inactivated HIV alone. Pancaspase, caspase-8, and caspase-9 inhibition blocked apoptosis induced by HCV, inactivated HIV, and HCV plus inactivated HIV. A caspase-9 inhibitor blocked apoptosis induced by HCV, HIV, and HCV-HIV comparably to pancaspase and caspase-8 inhibitors. HCV induced the activation of Bid cleavage and cytochrome C release. The addition of HIV substantially augmented this induction.
CONCLUSIONS: Our findings indicate that hepatocyte apoptosis is increased in the presence of HCV and HIV compared to HCV or HIV alone, and that this increase is mediated by DR4 and DR5 up-regulation. These results provide an additional mechanism for the accelerated liver disease progression observed in HCV-HIV co-infection.
Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21146890      PMCID: PMC3060969          DOI: 10.1016/j.jhep.2010.07.042

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  44 in total

Review 1.  Apoptosis: the nexus of liver injury and fibrosis.

Authors:  Ali Canbay; Scott Friedman; Gregory J Gores
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

2.  Identification and quantitation of HIV-1 in the liver of patients with AIDS.

Authors:  Y Z Cao; D Dieterich; P A Thomas; Y X Huang; M Mirabile; D D Ho
Journal:  AIDS       Date:  1992-01       Impact factor: 4.177

3.  Immunohistochemical evidence for human immunodeficiency virus-1 infection of liver Kupffer cells.

Authors:  C Housset; O Boucher; P M Girard; J Leibowitch; A G Saimot; C Bréchot; C Marche
Journal:  Hum Pathol       Date:  1990-04       Impact factor: 3.466

4.  The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors:  S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

5.  Involvement of TRAIL and its receptors in viral hepatitis.

Authors:  Bettina Mundt; Florian Kühnel; Lars Zender; Yasmin Paul; Hans Tillmann; Christian Trautwein; Michael Peter Manns; Stefan Kubicka
Journal:  FASEB J       Date:  2002-11-15       Impact factor: 5.191

6.  Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.

Authors:  Ellen M Tedaldi; Rose K Baker; Anne C Moorman; Carlos F Alzola; Jack Furhrer; Robert E McCabe; Kathleen C Wood; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2003-01-14       Impact factor: 9.079

7.  Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism.

Authors:  Neru Munshi; Anuradha Balasubramanian; Margaret Koziel; Ramesh K Ganju; Jerome E Groopman
Journal:  J Infect Dis       Date:  2003-09-30       Impact factor: 5.226

Review 8.  Pathology of AIDS-related liver disease.

Authors:  J H Lefkowitch
Journal:  Dig Dis       Date:  1994 Nov-Dec       Impact factor: 2.404

9.  Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis.

Authors:  Ariel E Feldstein; Ali Canbay; Paul Angulo; Makiko Taniai; Lawrence J Burgart; Keith D Lindor; Gregory J Gores
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

10.  Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury.

Authors:  Meagan J Walsh; Daina M Vanags; Andrew D Clouston; Michelle M Richardson; David M Purdie; Julie R Jonsson; Elizabeth E Powell
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

View more
  25 in total

Review 1.  HIV/hepatitis C coinfection natural history and disease progression.

Authors:  Maria D Hernandez; Kenneth E Sherman
Journal:  Curr Opin HIV AIDS       Date:  2011-11       Impact factor: 4.283

Review 2.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

Review 3.  After the cure: management of HCV after achievement of SVR.

Authors:  Zachary A Zator; Raymond T Chung
Journal:  Curr HIV/AIDS Rep       Date:  2013-12       Impact factor: 5.071

4.  Sex Differences, Cocaine Use, and Liver Fibrosis Among African Americans in the Miami Adult Studies on HIV Cohort.

Authors:  Gustavo Zarini; Sabrina Sales Martinez; Adriana Campa; Kenneth Sherman; Javier Tamargo; Jacqueline Hernandez Boyer; Colby Teeman; Angelique Johnson; Abraham Degarege; Pedro Greer; Qingyun Liu; Yongjun Huang; Raul Mandler; David Choi; Marianna K Baum
Journal:  J Womens Health (Larchmt)       Date:  2020-01-31       Impact factor: 2.681

5.  Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study.

Authors:  Richard K Sterling; Abdus S Wahed; Wendy C King; David E Kleiner; Mandana Khalili; Mark Sulkowski; Raymond T Chung; Mamta K Jain; Mauricio Lisker-Melman; David K Wong; Marc G Ghany
Journal:  Am J Gastroenterol       Date:  2019-05       Impact factor: 10.864

6.  Chronic immune activation is a distinguishing feature of liver and PBMC gene signatures from HCV/HIV coinfected patients and may contribute to hepatic fibrogenesis.

Authors:  Angela L Rasmussen; I-Ming Wang; Margaret C Shuhart; Sean C Proll; Yudong He; Razvan Cristescu; Chris Roberts; Victoria S Carter; Christopher M Williams; Deborah L Diamond; Janine T Bryan; Roger Ulrich; Marcus J Korth; Lisa V Thomassen; Michael G Katze
Journal:  Virology       Date:  2012-05-16       Impact factor: 3.616

7.  Neurocognitive impairment is worse in HIV/HCV-coinfected individuals with liver dysfunction.

Authors:  Jyoti Barokar; Allen McCutchan; Reena Deutsch; Bin Tang; Mariana Cherner; Ajay R Bharti
Journal:  J Neurovirol       Date:  2019-07-07       Impact factor: 2.643

8.  LncRNA Malat1 inhibition of TDP43 cleavage suppresses IRF3-initiated antiviral innate immunity.

Authors:  Wei Liu; Ziqiao Wang; Lun Liu; Zongheng Yang; Shuo Liu; Zhongfei Ma; Yin Liu; Yuanwu Ma; Lianfeng Zhang; Xuan Zhang; Minghong Jiang; Xuetao Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-09       Impact factor: 11.205

9.  Human immunodeficiency virus and liver disease forum 2012.

Authors:  Kenneth E Sherman; David Thomas; Raymond T Chung
Journal:  Hepatology       Date:  2013-11-22       Impact factor: 17.425

Review 10.  Pathogenesis of accelerated fibrosis in HIV/HCV co-infection.

Authors:  Wenyu Lin; Ethan M Weinberg; Raymond T Chung
Journal:  J Infect Dis       Date:  2013-03       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.